‘Targeting’ the epidermal growth factor receptor tyrosine kinase with gefitinib (Iressa®) in non-small cell lung cancer (NSCLC)
- 29 February 2004
- journal article
- review article
- Published by Elsevier in Seminars in Cancer Biology
- Vol. 14 (1) , 33-40
- https://doi.org/10.1016/j.semcancer.2003.11.005
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2003
- Studies with ZD1839 in preclinical modelsSeminars in Oncology, 2003
- Expression of constitutively activated EGFRvlll in non‐small cell lung cancerCancer Science, 2003
- STI571 (Gleevec™) as a paradigm for cancer therapyTrends in Molecular Medicine, 2002
- Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genesGenes & Development, 2001
- EGFR and cancer prognosisPublished by Elsevier ,2001
- Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial originNature, 1985
- Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cellsNature, 1984
- Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequencesNature, 1984
- A new avian erythroblastosis virus, AEV-H, carries erbB gene responsible for the induction of both erythroblastosis and sarcomasCell, 1983